Full Press Release Details
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Phase 3 studies in colorectal cancer, non-small cell lung cancer, and prostate cancer continue with over 70 percent enrollment completed.
REGN
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Phase 3 studies in colorectal cancer, non-small cell lung cancer, and prostate cancer continue with over 70 percent enrollment completed
Key Takeaway: Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Phase 3 studies in colorectal cancer, non-small cell lung cancer, and prostate cancer continue with over 70 percent enrollment completed
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism